Sees Q4 revenue up 14.5%-16.5%. The company said, “The company estimates net sales growth for the fourth quarter of 2025, versus the prior year period, to be in a range of approximately 14.5 to 16.5 percent on a reported basis, and 11 to 13 percent on an organic basis. Fourth quarter organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $0.48 to $0.52 and estimates adjusted EPS, excluding certain charges, of $0.77 to $0.79.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Notable companies reporting before tomorrow’s open
- Boston Scientific (BSX) Q3 Earnings Cheat Sheet
- Boston Scientific gets another winner with Nalu acquisition, says Leerink
- Boston Scientific’s Strategic Acquisition of Nalu Medical: A Growth Opportunity in the Neuropathic Pain Market
- Boston Scientific to acquire Nalu Medical for upfront cash payment of ~$533M